🔗 Share this article

Government ministers and leading parliamentarians have raised concerns that the United Kingdom's recent agreements with the US administration are "built on sand." This follows revelations that a recently announced deal on medicines, which promises zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond limited headline terms contained within government press releases.

A Deal Without Detail

The deal on drug tariffs, hailed as a "significant" achievement, exists as an "agreement in principle" without formal ratification. Critics have noted that the press releases from the UK and US governments present the deal in markedly contrasting terms. The British version focuses on securing "zero per cent tariffs" as a unique achievement, while the American announcement concentrates on the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has promised concessions to increase medicine costs in return for only a assurance from President Trump," commented David Henig, a trade expert. "It is documented he has form for not honouring his word."

A Pattern of Unreliability

Concerns have been amplified by Washington's move to pause the high-value digital accord, which was previously described as "a huge leap forward" in the bilateral relationship. The US cited a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions promised for British farmers as part of an earlier tariff deal have yet to be formally signed off by the US, despite a fast-approaching January deadline. "We have been informed that that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have expressed concerns that the government's agreements with the US are unstable and unpredictable. One minister reportedly said the series of agreements as "resting on shaky ground," while another characterized the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "The only thing more surprising than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Officials have downplayed the chances of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that instability is inherent in dealing with the current US leadership. However, they argue that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Nevertheless, delays have surfaced in implementing the broader trade deal. Promised access for British beef have yet to be finalized, and the commitment to "reduce steel tariffs to zero" has is still pending, with tariffs staying at 25%.

Moving forward, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.